You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGLT-2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)

Not yet recruiting
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis
  • Minneapolis, Minnesota
    University of Minnesota
Nov 20, 2023

Ketoses, Metabolic Trial (SGLT2 inhibitor + low-carb diet, + low-carb diet)

Not yet recruiting
  • Ketoses, Metabolic
  • SGLT2 inhibitor + low-carb diet
  • placebo + low-carb diet
  • (no location specified)
Dec 28, 2022

Lupus Nephritis, Chronic Kidney Diseases Trial in Hong Kong (Dapagliflozin 10mg Tab, Standard maintenance therapy)

Not yet recruiting
  • Lupus Nephritis
  • Chronic Kidney Diseases
  • Dapagliflozin 10mg Tab
  • Standard maintenance therapy
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 24, 2023

The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Recruiting
  • Metabolic Disease
  • Diabetes
  • SGLT-2 inhibitors
  • Samsun, İlkadım, Turkey
    Samsun Education and Research Hospital
Jun 14, 2023

Acute Kidney Injury Trial (SGLT2 inhibitor)

Not yet recruiting
  • Acute Kidney Injury
  • SGLT2 inhibitor
  • (no location specified)
Nov 3, 2023

Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • +3 more
  • Dapagliflozin 10mg Tab
  • Placebo
  • Moscow, Russian Federation
    National Medical Research Center for Cardiology, Ministry of Hea
Mar 20, 2023

Diabetes, Heart Failure Trial in Singapore (Dapagliflozin 10 MG [Forxiga])

Completed
  • Diabetes Mellitus
  • Heart Failure
  • Dapagliflozin 10 MG [Forxiga]
  • Singapore, Singapore
    National Heart Centre Singapore
Jan 13, 2023

Type 2 Diabetes Trial (SGLT2 inhibitor)

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • SGLT2 inhibitor
  • (no location specified)
Feb 12, 2023

Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)

Completed
  • Healthy Volunteers
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

Cystinuria Trial in San Francisco (Dapagliflozin)

Not yet recruiting
  • Cystinuria
  • San Francisco, California
    University of California, San Francisco
Sep 13, 2022

Postoperative Hyperglycemia, Stress Hyperglycemia Trial (SGLT2 inhibitor, Placebo)

Not yet recruiting
  • Postoperative Hyperglycemia
  • Stress Hyperglycemia
  • SGLT2 inhibitor
  • Placebo
  • (no location specified)
Mar 29, 2022

Heart Failure Acute, Ventilator Lung Trial in Taipei (SGLT2 inhibitor)

Recruiting
  • Heart Failure Acute
  • Ventilator Lung
  • SGLT2 inhibitor
  • Taipei, Taiwan
    National Taiwan University Hospital
Nov 16, 2023

Type 2 Diabetes Trial in Seoul (SGLT2 inhibitor)

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • SGLT2 inhibitor
  • Seoul, Seodaemun-gu, Korea, Republic of
    Severance Hospital
Nov 17, 2023

SGLT-2 Inhibitors in the Treatment of Ascites

Recruiting
  • Ascites Hepatic
  • +2 more
  • SGLT2 inhibitor
  • Palermo, Italy
  • +1 more
Aug 11, 2023

SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Recruiting
  • Coronary Artery Disease
  • Diabete Mellitus
  • SGLT2 inhibitor
  • Beijing, Beijing, China
    Beijing Anzhen Hospital
Apr 12, 2022

Chronic Kidney Diseases, Diabetes, PreDiabetes Trial in Vienna (Therapeutic carbohydrate restriction combined with an

Recruiting
  • Chronic Kidney Diseases
  • +3 more
  • Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor
  • Vienna, Austria
    6th Medical Department with Nephrology and Dialysis, Clinik Otta
Oct 16, 2023

Diabete Type 2 Trial in El Sadat (Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG)

Completed
  • Diabete Type 2
  • Sitagliptin 50 mg
  • +3 more
  • El Sadat, Egypt
    University of Sadat City
Apr 27, 2022

Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Porto, Portugal
  • +3 more
Aug 9, 2023

Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)

Not yet recruiting
  • Fatty Liver, Nonalcoholic
  • SGLT2 inhibitor
  • (no location specified)
Oct 31, 2023

Chronic Coronary Syndrome, Atrial Fibrillation Trial (Dapagliflozin 10mg Tab, Placebo Tab)

Not yet recruiting
  • Chronic Coronary Syndrome
  • Atrial Fibrillation
  • Dapagliflozin 10mg Tab
  • Placebo Tab
  • (no location specified)
May 9, 2023

Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)

Completed
  • Fatty Liver Disease
  • Canagliflozin 100mg
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Feb 28, 2023

Heart Failure Trial (Finerenone, Empagliflozin)

Not yet recruiting
  • Heart Failure
  • (no location specified)
Sep 5, 2023

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023

Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan

Recruiting
  • Heart Failure
  • +2 more
  • SGLT2 inhibitor
  • Roma, RM, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023